Stuart Cook (@stuartacook1) header
Stuart Cook (@stuartacook1) profile picture

MD PhD. Targeting regeneration and ageing. Founder Enleofen and VVB Bio. Views my own.

UK or Singapore, depends
Joined September 2015
Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)Photo by Stuart Cook (@stuartacook1)
The David Sinclair (@davidasinclair) $720,000,000 Resveratrol Train Wreck Video shoutouts: - Prof. Matt Kaeberlein (@mkaeberlein) - Prof. Brian Kennedy (@BKennedy_aging) - Dr. Peter Attia (@PeterAttiaMD) - Prof. Richard Miller - Prof. Jeffery Flier (@jflier)
77
200
115
1,015
628,086
A ground-breaking study led by @unibirmingham & @UniFAU reveals that #Fibroblast cells hold the key to resolving joint inflammation 🔑 The discovery could revolutionise future #Arthritis treatments 🔬 ➡️bit.ly/3TaTrwe #Inflammation #Ageing #Research
6
25
1,893
Stuart Cook retweeted
"The average R&D efficiency of big pharma was $6.16 billion total R&D expenditures per new drug." 😱 And remember, that's the average, meaning ~half are higher than that! @ideapharma $XBI sciencedirect.com/science/ar…
12
25
6
134
23,104
Violence against women & girls remains one of most prevalent & pervasive human rights violations. Globally, estimated 736M women almost 1:3 subjected physical and/or sexual intimate partner violence, non-partner sexual violence or both, at least once life. un.org/en/observances/ending…
1
10
27
5,799
Stuart Cook retweeted
Only 12% of drug approvals in the past 6 years were internally-developed Big Pharma programs! @timmermanreport @LifeSciVC
3
23
1
75
13,807
Stuart Cook retweeted
Any guesses on what our next XPRIZE competition will be for? History will be made on Nov. 29 at 10:30am ET / 7:30am PT when we announce the launch of our largest prize ever. You don’t want to miss out. Register to join the livestream of our launch here. xprize.org/health
10
11
3
18
7,997
Color me surprised: another AI drug company making the great migration from an external partnership/ platform model to internal pipeline. Atomwise signed >750 partnerships 🤯 “But none of those molecules have made it to the clinic.” From @AndrewE_Dunn’s coverage in Endpoints, summarized in Decoding Bio.
10
22
3
143
56,225
Fibrogen’s phase 3 ZEPHYRUS-1 shows no effect on FVC at 48 weeks. Sad to see another drug fail at such a late stage, but a fantastic effort to deliver this study! We must learn and move forwards #cureipf ⁦@ActionPFcharity⁩ ⁦@asthmalunguk⁩ investor.fibrogen.com/news-r…
6
14
2,496
On Sunday at the ADA meeting in San Diego I’ll announce the results of our IL-2 trial to slow up the loss of insulin production in children newly diagnosed with type 1 diabetes.
1
6
14
3,239
Current and investigational medications for the treatment of sarcopenia sciencedirect.com/science/ar…
1
2
10
1,733
Elsevier is losing editors
323
7,512
1,623
24,144
4,459,512
Stuart Cook retweeted
We bet you've been waiting for this announcement! Wait no more - FinnGen DF9 (N=377,277) GWAS results and summary statistics are now freely available! You can browse the results with our web browser and/or download them. More info: finngen.fi/en/access_results #OpenScience #Genomics
2
37
3
107
21,908
As a result of our partnership with Enleofen, we have launched clinical development of our first-in-class IL-11 inhibitor antibody BI 765423, which aims to improve patient outcomes in fibrotic diseases. Learn more: https://nitter.cf/t.co/vM79HEwmM3 #Innovation
12
16
1
32
5,145
Eighty years ago today – April 26th 1943 – Philip Alexander Poole-Wilson was born. He became a pioneer in the field of heart failure and one of 🇬🇧's most cherished academic cardiologists With family permission, this 🧵remembers ‘PPW’ and his invaluable contributions to medicine
10
35
7
131
50,935
"Why do you love biotech?" When Stelios Papadopoulos, aka the Godfather of biotech, was once asked this question, he said: "What intrigues me the most is this whole process of taking a casual idea in the lab. Sometimes you sit with a cup of coffee and you say, gee, how about this? And then, 25 years later, there's somebody with kidney cancer who responds to a drug... That only happened because of this unique interplay of basic scientists, drug developers, clinical scientists, people betting money on stocks, people who build companies, regulators, journalists, writers, and movie makers. It's a fascinating laboratory that's multidisciplinary and highly complex. And all of this, in the end, is for something good. Lives are saved, pain is relieved. I don't think there's anything more fascinating than this in life. There is fascinating stuff, eg. understanding string theory. It's intellectually, and potentially satisfying, but it's hard to see the immediate positive effect on human life..." (from @NatureBiotech's First Rounders Podcast with Brady Huggett)
5
47
1
245
68,569
Latest from our lab co-led by Ben Ng, and a continuation of our previous aorta story! 🥳 🍾To my first last author research paper and first-time publication in ATVB 🥂 Grateful to my mentor @stuartacook1, and thankful to the editors/reviewers for their helpful suggestions! ☺️
Genetic and antibody-mediated neutralization of Interleukin-11 attenuates emphysematous lung disease in a mouse model of Marfan Syndrome @WeiWenLim23 @stuartcook1 ahajrnls.org/40ive8i
1
1
6
1,084